Skip to main content
Funded Studies

Thomas N. Sager, PhD

Prinicipal Scientist, In vivo Neurobiology; Section of Neurodegeneration at H. Lundbeck A/S

Location: Valby Denmark

Dr. Thomas Sager received his MSc degree from the University of Copenhagen, where he also received his PhD in neuroscience. Dr. Sager has worked for several years in the pharmaceutical industry with particular focus on CNS disorders. Since 1999, Dr. Sager has been working at H. Lundbeck where he is Principal Scientist. Dr. Sager´s research interests are focused on in vivo neuropharmacology ranging from early target identification studies to late stage pre-clinical pharmacological evaluation of emerging therapeutic targets, primarily within Parkinson's disease.

Associated Grants

  • GPR88, a new PD target involved in the modulation of basal ganglia circuitry


  • Hif Prolyl Hydroxylase Inhibitors: New Treatment Potential against Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.